Callan JMB CEO, Wayne Williams Invited to Attend the 50th International GMP Conference on March 2-5, 2026

Rhea-AI Summary

Callan JMB (NASDAQ:CJMB) announced that Founder, CEO and Chairman Wayne Williams will attend the 50th International GMP Conference on March 2-5, 2026 in Athens, Georgia.

The conference, co-sponsored by the University of Georgia College of Pharmacy and the FDA, focuses on pharmaceutical regulation, technology and supply-chain integrity.

News Market Reaction – CJMB

+4.52%

14 alerts

+4.52% News Effect

+25.2% Peak in 26 hr 49 min

+$368K Valuation Impact

$9M Market Cap

0.2x Rel. Volume

On the day this news was published, CJMB gained 4.52%, reflecting a moderate positive market reaction. Argus tracked a peak move of +25.2% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $368K to the company's valuation, bringing the market cap to $9M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference edition: 50th Conference dates: March 2-5, 2026 Conference start year: 1976

3 metrics

Conference edition 50th International GMP Conference iteration

Conference dates March 2-5, 2026 International GMP Conference schedule

Conference start year 1976 Conference hosted annually since 1976

Market Reality Check

Price: $1.75 Vol: Volume 142,337 vs 20-day ...

low vol

$1.75 Last Close

Volume Volume 142,337 vs 20-day average 628,228 (volume_relative 0.23), showing muted trading ahead of the news. low

Technical Shares at $1.55, trading below 200-day MA of $3.76 and 74.71% below the 52-week high.

Peers on Argus

Sector scanners flag 3 logistics peers moving down together (median move -13.5%)...

3 Down

Sector scanners flag 3 logistics peers moving down together (median move -13.5%), while CJMB was down 4.91%, pointing to broader sector pressure rather than stock-specific trading into this conference headline.

Historical Context

5 past events · Latest: Jan 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 20	Conference participation	Positive	-18.2%	Announcement of participation in DealFlow Discovery investor conference.
Jan 15	Revenue-sharing deal	Positive	+275.0%	Multi-asset therapeutic pipeline agreement with Attune projecting sizable revenue.
Jan 12	Strategic pivot	Positive	+3.0%	Pivot to GLP-1 cold-chain infrastructure and Texas cGMP facility retrofitting.
Nov 14	Q3 2025 earnings	Neutral	+3.6%	Q3 2025 results showing modest revenue with wider operating and net losses.
Nov 13	Facility agreement	Positive	-9.2%	Preliminary agreement to install oral drug delivery equipment in Texas facility.

Pattern Detected

CJMB has shown mixed reactions to positive news, with both sharp gains and notable selloffs around operational and partnership announcements.

Recent Company History

Over the last several months, CJMB has issued a series of business and financing updates. A January 2026 teaming agreement with Attune projected $50–$75 million in combined revenue and saw a +275% reaction. A strategic pivot to GLP‑1 cold‑chain infrastructure and Q3 2025 results with $1.4M quarterly revenue drew modest gains. By contrast, conference participation and facilities agreements sometimes coincided with double‑digit declines. Today’s conference invitation continues a pattern of visibility and positioning within regulated healthcare logistics.

Market Pulse Summary

This announcement highlights CJMB’s leadership presence at the 50th International GMP Conference, a ...

Analysis

This announcement highlights CJMB’s leadership presence at the 50th International GMP Conference, a forum co-sponsored by the University of Georgia College of Pharmacy and the FDA. It reinforces the company’s positioning at the intersection of pharmaceutical logistics and regulatory standards. In context of prior strategic pivots and partnership deals, investors may watch how insights from this event translate into concrete contracts, expanded cold-chain capabilities, and progress toward improving revenue scale and operating performance over subsequent updates.

Key Terms

gmp, u.s. food & drug administration (fda), cold chain logistics

3 terms

gmp regulatory

"50th International GMP Conference, on March 2-5, 2026 in Athens, Georgia."

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

u.s. food & drug administration (fda) regulatory

"co-sponsored by the University of Georgia College of Pharmacy and U.S. Food & Drug Administration (FDA)."

The U.S. Food and Drug Administration is the federal agency that evaluates and approves medicines, medical devices, vaccines, certain food products and related labeling and safety — acting as the gatekeeper that determines which health and food products can be sold and how they are described. For investors, FDA decisions shape whether a product can reach customers, the timing and size of potential revenues, and the company's risk profile, so regulatory approvals, rejections or safety actions are major value drivers.

cold chain logistics technical

"through fulfillment, storage, monitoring, and cold chain logistics services, today announced"

Cold chain logistics is the system of transporting, storing and handling temperature-sensitive goods—like vaccines, biologics, perishable foods—while keeping them within tightly controlled cold temperatures from origin to destination. Investors care because failures can ruin product value, trigger recalls or regulatory action, and create recurring revenue opportunities for providers of specialized storage, transport equipment and monitoring services; think of it as a refrigerated pipeline that protects product quality and revenue.

AI-generated analysis. Not financial advice.

SPRING BRANCH, Texas, March 02, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB), (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced that Wayne Williams, Chief Executive Officer, Chairman & Founder, has been invited to attend the 50th International GMP Conference, on March 2-5, 2026 in Athens, Georgia.

The conference is co-sponsored by the University of Georgia College of Pharmacy and U.S. Food & Drug Administration (FDA). Hosted annually since 1976, the conference offers a global forum where regulatory authorities, industry leaders, and experienced professionals come together to address and discuss emerging ideas at the intersection of the pharmaceutical and regulatory industries.

“It’s an honor to attend this prestigious conference,” said Wayne Williams, Founder and Chief Executive Officer of Callan JMB. “While our industry is navigating rapid technological advances and regulatory evolution, Callan JMB aims to remain at the forefront of healthcare logistics and emergency preparedness. It is a particularly important time to be discussing the future, and I look forward to contributing to the dialogue and bringing back insights that further our mission to ensure the safety and integrity of essential products through technology-enabled, efficient distribution.”

For more information about the International GMP Conference, visit https://internationalgmp.com/.

About Callan JMB Inc.
Callan JMB Inc. is a vertically integrated logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer a gold standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254

FAQ

Who from Callan JMB (CJMB) will attend the 50th International GMP Conference on March 2-5, 2026?

Wayne Williams, Founder, Chief Executive Officer and Chairman, will attend the March 2-5, 2026 conference. According to Callan JMB, he will participate to discuss healthcare logistics, regulatory evolution, and advances in cold-chain and emergency preparedness.

What is the purpose of Callan JMB CEO Wayne Williams attending the March 2026 International GMP Conference?

The purpose is to engage with regulators and industry leaders on emerging GMP and cold-chain topics. According to Callan JMB, Williams aims to bring back insights on technology-enabled distribution and supply-chain integrity for healthcare products.

Where and when is the 50th International GMP Conference that CJMB CEO will attend?

The conference takes place in Athens, Georgia from March 2-5, 2026. According to Callan JMB, the event is co-sponsored by the University of Georgia College of Pharmacy and the U.S. Food & Drug Administration.

Will Callan JMB (CJMB) discuss regulatory or product matters at the March 2026 GMP Conference?

Callan JMB expects to participate in discussions on regulatory evolution and supply-chain integrity. According to Callan JMB, the company will focus on technology-enabled logistics, emergency preparedness, and ensuring product safety in distribution.

How can investors learn more about the International GMP Conference and CJMB's participation in March 2026?

Investors can review conference details and agenda on the official conference website. According to Callan JMB, additional information about the event is available at the International GMP Conference website for scheduling and topics.